Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riabni vs Rituximab in Rheumatoid Arthritis
NCT02792699Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Amgen. Primary endpoints: Area Under the Serum Concentration-time Curve From Time 0 to Infinity at Week 12 and Maximum Observed Drug Concentration at Week 12. Started May 2016; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02792699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792699.